Gene · 83667
Papers1,838
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,838
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Autophagy in ovary: protective roles, pathological consequences, and unresolved issues. | J Ovarian Res | 2025 | 40999527 | PubTator, text mining | PubMed |
| Integrative assessment of RNA sequencing and in silico analysis to pinpoint mRNAs, lncRNAs, and circRNAs interactions with miRNAs underlying arsenic-induced neurotoxicity. | BMC Genomics | 2025 | 40999364 | PubTator, text mining | PubMed |
| Bio fluid exosomes: promises, challenges, and future directions in translational medicine. | J Transl Med | 2025 | 40988065 | PubTator, text mining | PubMed |
| GTEx pro enables accurate multi-tissue gene expression analysis using robust normalization and batch correction. | Sci Rep | 2025 | 40987889 | PubTator, text mining | PubMed |
| Reduced serum sestrin 2 levels in Hashimoto's disease: a cross-sectional study on a potential pathophysiological and diagnostic role. | Endocr Connect | 2025 | 40956676 | PubTator, text mining | PubMed |
| Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transduction. | Life Sci Alliance | 2025 | 40897470 | PubTator, text mining | PubMed |
| Structural basis for the dynamic regulation of mTORC1 by amino acids. | Nature | 2025 | 40836086 | PubTator, text mining | PubMed |
| Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2025 | 40830968 | PubTator, text mining | PubMed |
| The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC). | Cancer Cell Int | 2025 | 40830878 | PubTator, text mining | PubMed |
| The ATF4-glutamine axis: a central node in cancer metabolism, stress adaptation, and therapeutic targeting. | Cell Death Discov | 2025 | 40830338 | PubTator, text mining | PubMed |
| Emerging implications of N6-methyladenosine in prostate cancer progression and treatment. | Cell Death Discov | 2025 | 40830264 | PubTator, text mining | PubMed |
| SESN2 maintains cartilage homeostasis by SREBP1-mediated lipid metabolism during osteoarthritis progression. | iScience | 2025 | 40822351 | PubTator, text mining | PubMed |
| SREBF1-mediated SND1 transcriptional activation promotes prostate cancer progression via MTDH interaction through the SESN2/AMPK/mTOR axis. | J Transl Med | 2025 | 40775338 | PubTator, text mining | PubMed |
| SMAD3 orchestrates RNF167 and STAMBPL1-mediated Sestrin2 ubiquitination to drive gastric cancer progression. | Cell Div | 2025 | 40751214 | PubTator, text mining | PubMed |
| Cryo-EM structures of amino acid sensors bound to the human GATOR2 complex. | Cell Rep | 2025 | 40742811 | PubTator, text mining | PubMed |
| mTORC1 senses glutamine and other amino acids through GCN2. | EMBO J | 2025 | 40691417 | PubTator, text mining | PubMed |
| Artemisinin synergizes with CCCP in autophagic cell death induction via ER stress in uveal melanoma. | iScience | 2025 | 40686605 | PubTator, text mining | PubMed |
| Chronic exposure to PFAS triggers systems-level cellular reprogramming independent of their bioaccumulation. | bioRxiv | 2025 | 40672246 | PubTator, text mining | PubMed |
| Sestrin2 Overexpression Inhibits Proliferation and Epithelial-Mesenchymal Transition and Induces Autophagy Through the AMPK/mTOR Signaling Pathway in Human Prostate Cancer Cells. | Prostate Cancer | 2025 | 40661871 | PubTator, text mining | PubMed |
| SESN2 inhibits tubular exosome secretion and diabetic kidney disease progression by restoring the autophagy‒lysosome pathway. | Int J Biol Sci | 2025 | 40612680 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/83667/papers?page=5